

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION AGREEMENT WITH OYMOTION
TECHNOLOGIES CO., LTD.***

This announcement is made by MicroPort NeuroScientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 28 May 2026, MicroPort NeuroTech (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司, “**MP NeuroTech Shanghai**”), a wholly-owned subsidiary of the Company, entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with OYMotion Technologies Co., Ltd.* (上海傲意信息科技有限公司, “**OYMotion**”). Pursuant to the Strategic Cooperation Agreement, MP NeuroTech Shanghai and OYMotion will leverage their respective technological and industrial strengths to pursue the deep integration of brain-computer interface (“**BCI**”) and exoskeleton robot systems, undertake long-term research and development collaboration, explore potential application scenarios and jointly advance the commercialisation of frontier brain science technologies. The Group will focus on BCI technology research and development, product design and commercialisation, whilst OYMotion will focus on providing high-performance, high-compatibility exoskeleton robot devices and intelligent control solutions. Through technological synergy and resource integration, the parties will jointly enhance the functionality, performance and usability of BCI systems.

INFORMATION ABOUT THE PARTIES

The Company

The Company is a leading enterprise in China's brain science sector, with an industry-leading position in the treatment of neurovascular diseases. The Company has independently developed a number of internationally leading neurointerventional medical devices and has accumulated deep expertise in interventional device design, clinical trials and commercialisation. The Company is engaged in the development of BCI products across multiple modalities, including interventional forms, with the aim of achieving the productisation and commercialisation of BCI technology.

The Company has previously established the Chaos BCI Research Institute, marking a pivotal step into the frontier BCI technologies and driving the translation of frontier brain science technologies into clinical applications.

MP NeuroTech Shanghai is a wholly-owned subsidiary of the Company, which is established in the PRC with limited liability and principally engaged in the R&D, manufacture and sale of innovative neuro-interventional medical devices.

OYMotion

OYMotion is a leading enterprise in China's non-invasive BCI sector. OYMotion focuses on non-invasive brain and myoelectric neural signal acquisition, AI-based motor intent decoding and multi-degree-of-freedom robot development. OYMotion possesses a mature product matrix encompassing bionic hands and dexterous hands, in-house core component manufacturing capabilities and deep industrialisation experience in the field of rehabilitation engineering.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, as at the date of this announcement, OYMotion and its ultimate beneficial owners are third parties independent of and not connected with the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

REASONS FOR AND BENEFITS OF THE COOPERATION

Through the cooperation, the Group and OYMotion aim to jointly drive innovative applications of BCI technology in the fields of medical rehabilitation and human-machine interaction. By combining the Group's strengths in brain science technology research and development, clinical translation and commercialisation with OYMotion's capabilities in high-performance, high-compatibility exoskeleton robot devices and intelligent control solutions, the parties expect to continuously optimise the functionality, performance and

user experience of BCI systems. Through a deeply integrated industry-academia-research-application model, the parties intend to deliver high-quality innovative solutions for the brain disease sector and contribute to the broader development of the brain science ecosystem.

The Board considers that the entering into of the Strategic Cooperation Agreement is in the ordinary course of business of the Group and on normal commercial terms, and is in the interests of the Group and the shareholders of the Company as a whole.

GENERAL INFORMATION

The entering into of the Strategic Cooperation Agreement does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules and is not subject to any reporting, announcement or independent shareholders' approval requirements under the Listing Rules.

The Board wishes to emphasise that the Strategic Cooperation Agreement establishes a framework for a long-term strategic partnership between the parties. For any specific projects implemented under the strategic cooperation, the Company will comply with the applicable requirements under the Listing Rules and make further disclosure as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, May 28, 2026

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.

* *For identification purpose*